IRVINE, Calif., Aug. 2, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces yet another new peer-reviewed study demonstrating that treatment decisions informed by Proove Opioid Risk® technology results in better patient outcomes. This study, entitled "A prospective, longitudinal study to evaluate the clinical utility of a predictive algorithm that detects risk of opioid use disorder" has been accepted for publication by the Journal of Pain Research (Impact Factor: 2.96).
Researchers Katrina Lewis, M.D. of Benefits Healthcare System's Pain Medicine department in Montana, Maneesh Sharma, M.D. of the Interventional Pain Institute in Maryland, and Gregory Smith of Comprehensive Pain Relief Group in California teamed with Proove® scientists to conduct a multi-center, prospective study across 100 clinics involving 5,397 patients to determine the clinical utility of an algorithm-based precision medicine profile to assess risk for opioid use disorder (OUD). Results show that when clinicians use Proove Opioid Risk® profile to guide treatment decisions, patients experience better pain management showing significantly improved (p ≤0.05) pain levels by the follow-up visit with an average pain reduction of 3.4 points in the NRS (p =3.39 x10-108). At least 90% of physicians stated Proove Opioid Risk® benefited their patients, with 78% indicating "significant benefit."
The clinical utility of the Proove Opioid Risk® profile is two-fold; it provides clinically actionable recommendations that can be used to 1) prevent OUD through limiting unnecessary opioid prescriptions, and 2) reduce pain independent of risk for developing OUD.
Dr. May Hafez, Clinical Director at Proove® explains, "Clinical studies continue to validate that Proove®'s precision medicine technology provides clinicians with a tool to better inform decision-making. This study clearly shows that physicians believe Proove Opioid Risk® has significant benefit and results in treatment changes which produce a very meaningful reduction in pain."
Proove® CEO Brian Meshkin explains, "With the dual public health crises of chronic pain and opioid abuse, only Proove® technology has shown repeatedly in published, peer-reviewed clinical studies to help clinicians make better treatment decisions resulting in a win-win – a 50% reduction in pain and up to a 96.7% accuracy in identifying patients at risk for opioid abuse – benefiting every stakeholder in the healthcare system."
About Proove® Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals. Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
SOURCE Proove Biosciences, Inc.